key: cord-0864708-u8mu4yga
authors: Frieden, Thomas R.; Cash-Goldwasser, Shama
title: Of Masks and Methods
date: 2020-11-18
journal: Ann Intern Med
DOI: 10.7326/m20-7499
sha: 58961a995786266754ee993de7caf4283c9093ca
doc_id: 864708
cord_uid: u8mu4yga

In their article, Bundgaard and colleagues report the results of a unique randomized controlled trial of masks in the community to mitigate SARS-CoV-2 infection. The trial addresses the question of personal protection to mask wearers when others are not wearing masks and not the question of the effectiveness of widespread mask wearing in reducing community transmission. The editorialists discuss the findings and their concerns about the trial design.

the most disruptive health event in a century. In less than a year, it will have killed at least 1.5 million people and cost the global economy more than $20 trillion. Although progress toward a vaccine has been fast, core public health interventions remain the mainstay of control and will continue to be essential after vaccines become available. Strategic closure of risky indoor environments, such as bars, restaurants, and choirs, reduces spread. Testing, rapid isolation, contact tracing, and quarantine prevent cases and clusters from spreading. Use of face masks has emerged as a powerful tool to reduce the health and economic harms of the pandemic (1).

The fact that viral loads are highest just before and early in the course of illness provides the theoretical basis for widespread community mask use as source control, and the evidence that wearing of masks prevents spread to others is compelling (1) . Observational studies have shown that mask use in the community is associated with a significantly lower risk for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2). Although evidence suggests that masks protect wearers from infection (3) and there is mechanistic evidence that masks not only block release of respiratory droplets but also reduce wearer exposure (4), whether masks protect wearers from infection has been the subject of controversy. The protection a mask offers the wearer depends in part on the duration, location (for example, home vs. public), and intensity (for example, health care vs. community) of exposure; type of mask; and consistency of use. In addition, the methods used to evaluate whether masks protect wearers affect study results.

The DANMASK-19 (Danish Study to Assess Face Masks for the Protection Against COVID-19 Infection) randomized controlled trial (5) was done during spring 2020 in Denmark, when use of masks in the community was not recommended by the Danish Health Authority but other public health and social measures to limit transmission of SARS-CoV-2 were in effect. Intervention group participants received 50 disposable surgical face masks and instructions to wear a mask while outside home for 1 month. The primary outcome was infection with SARS-CoV-2, defined as 1) positive results of lateral flow testing for anti-SARS-CoV-2 IgM or IgG antibodies at 1 month, 2) positive results of polymerase chain reaction testing for SARS-CoV-2 at 1 month and symptoms compatible with COVID-19, or 3) diagnosis of COVID-19 by a health care practitioner. Participants with positive baseline results on an antibody test were excluded from analyses.

The primary outcome according to the protocol occurred in 1.8% of participants (42 of 2392) in the intervention group and 2.1% (53 of 2470) in the control group. In the intention-to-treat analysis, the intervention group had 0.3 percentage point (95% CI, À0.4 to 1.2 percentage point) fewer SARS-CoV-2 infections than the control group. Across all analyses (intention-to-treat, per protocol, and with multiple imputation for missing data), odds ratios were approximately 0.8, consistent with a 20% reduction in incident SARS-CoV-2 infection if masks are recommended. The sample size was insufficient to determine the statistical significance of a 20% reduction.

The specifics of the study setting limit not only its statistical power but also the generalizability of findings. The study was done in a setting with relatively low transmission: During the first week of May, the daily incidence of new confirmed COVID-19 cases in Denmark was roughly one third of that in the United Kingdom and one quarter of that in the United States (6) . Furthermore, the study was underpowered for subgroup analyses by occupation, time out of home (although more time out of home was associated with a greater trend toward protection, as shown in Supplement Figure 2 [5]), and other factors. Thus, the potential benefit of mask wearing in particular circumstances or settings could not be assessed.

Perhaps the most important limitation of this study was the use of antibody tests to diagnose COVID-19. Of COVID-19 diagnoses in this study, 84% (80 of 95) were made by antibody testing. The accuracy of anti-SARS-CoV-2 antibody tests varies widely (7) . Although an internal validation study of the assay used in DANMASK-19 estimated a specificity of 99.5%, the manufacturer reported (www.accessdata.fda.gov/cdrh_docs/presentations/maf /maf3285-a001.pdf) a specificity of 97.5% (CI, 91.3% to 99.3). If test specificity was 98.5% and the 1.5% (1 À specificity) chance of a false-positive result was due to random laboratory variation, Bayes' law implies that all of the antibody-positive results in both intervention and control groups could have been false positives. False positivity due to cross-reactive antibodies would have resulted in baseline exclusion, so the actual rate of false positives in participants after 1 month may be low. Nevertheless, given the very low (at most 2%) prevalence of infection, many of the follow-up positives may have been falsely positive and would be randomly distributed between intervention and control groups. This would bias the study's findings toward the null.

In addition, a mask recommendation or self-report of use does not equate with correct mask wearing; among persons who wear masks during high-risk exposures, risk for infection may be reduced significantly (3). In DANMASK-19, only 46% of those in the intervention group reported adherence to the intervention. Women may be more likely to adhere to public health recommendations than men (8) . Among female participants, the decreased odds of infection with SARS-CoV-2 among those in the intervention group compared with those in the control group approached statistical significance (odds ratio, 0.65 [CI, 0.38 to 1.12]); this trend could also have been biased toward the null by similar numbers of false positives in both groups.

Community mask use can substantially reduce risk for SARS-CoV-2 transmission, especially when enough people use them and when mask use is combined with other effective public health and social measures. Multiple observational studies have documented an association between mask mandates and reduced COVID-19 incidence (9) . Although randomized controlled trials are often presumed to provide the highest-quality data, observational studies may in some settings be more accurate and can overcome some limitations of other data sources (10) .

Although no single strategy can control the pandemic, widespread masking in the community can mitigate spread as part of a comprehensive approach. Masks have been shown to protect others and, despite the reported results of this study, probably protect the wearer. Maximum benefit of masking is likely to result from the combination of source control and wearer protection (1). If everyone wears a mask when near others, everyone is safer.

Scientific brief: community use of cloth masks to control the spread of SARS-CoV-2

COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis

Case-control study of use of personal protective measures and risk for SARS-CoV 2 infection

Effectiveness of face masks in preventing airborne transmission of SARS-CoV-2. m. Sphere. 2020

Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers. A randomized controlled trial

Coronavirus pandemic (COVID-19)

Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane

Gender differences in COVID-19 attitudes and behavior: panel evidence from eight countries

Weekly COVID-19 science review October 3-9. Resolve to Save Lives

Evidence for health decision making -beyond randomized, controlled trials